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Abstract 
Background: Data are skewed on the role of Socio-demographic, nutritional and adherence related factors on 
the influence of nevirapine plasma concentrations among Kenyan population. This study rigorously determined 
these three factors on nevirapine plasma concentrations among HIV patients receiving HIV treatment in two 
regions known for high prevalence of HIV and long duration of ART uptake.Methods: Blood samples were 
collected from 377 consenting HIV adult patients receiving an NVP-based first-line ART regimen. A detailed 
sociodemographic questionnaire was administered. NVP plasma concentration was measured by liquid 
chromatography - tandem mass spectrometry (LC-MS/MS). Results: The majority (59.2%) of the patients were 
female, 72.2% were from western Kenya (predominantly Nilotic speaking community). The patients’ mean age 
was 41.6 (SD ± 11.5) years and the mean duration of ART was 5.1 (SD ± 4.8) years. The median BMI of the 
patients was 25 kg/m2 (IQR = 22.2 - 28.7 kg/m2). The majority 81.2% were receiving 3TC/NVP/TDF ART 
regimen, 30% had changed their initial ART regimen with 54.4% reporting missing taking current ARVs. 
Overall NVP plasma levels ranged from 4-44207 ng/mL (median 6213 ng/mL, IQR 3097–8606.5 ng/mL). There 
were 105 (25.5%) participants with NVP levels of <3100 ng/mL, associated with poor viral suppression. 
Multivariate linear regression analysis showed region of origin (adjusted β 976, 95% CI, 183.2 to 1768.82; p = 
0.016), gender (adjusted β 670, 95% CI, 293.6 to 1634.2; p = 0.047), education level (adjusted β -39.0779, 95% 
CI, -39.07 to 1085.7; p = 0.068), initial ART regimen type (adjusted β = -548.1, 95% C = -904.2 to -192; p 
=0.003) and ARV uptake in the past 30 days (adjusted β = -1109, 95% C = -2135 to -83; p =0.034) remained 
independently associated with NVP plasma levels.Conclusion: NVP plasma concentration is highly 
heterogenous among Kenyan population with a significant proportion of patients reporting levels of <3100 ng/ml, 
correlated with poor viral suppression. The host pharmacoecologic factors, such as gender, age, weight, 
education level, region of origin (ethnicity), ART regimen type and adherence, are key in influencing NVP 
plasma concentration. Taking these factors into consideration, HIV treatment may be personalized to achieve 
optimal treatment success.  
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Background 
Globally, the introduction of antiretroviral therapy (ART) as treatment for HIV infections has greatly reduced 
mortality and morbidity among patients living with HIV (UNAIDS, 2020). Kenya is steadily on the track for 
scale up of ART uptake in line with the 2015 World Health Organization recommendations requiring immediate 
initiate ART treatment to people testing HIV positive regardless of their CD4 or viral load (UNAIDS, 2016). By 
the end of 2019, about 74% adults and 73% children in Kenya needing ART were receiving ART treatment 
(UNAIDS, 2020). A remarkable proportion of these patients (68%) were virally suppressed (UNAIDS, 2020). At 
the time of the study, the first-line ART guidelines for children, youth and adults in Kenya typically contained a 
backbone of two nucleoside reverse transcriptase inhibitors (NRTIs; zidovudine [AZT], stavudine [d4T], 
tenofovir [TDF] or lamivudine [3TC]), plus one non-nucleoside reverse transcriptase inhibitor (NNRTI): either 
nevirapine (NVP) or efavirenz (EFV) (NASCOP, 2016).  
Nevirapine has been widely used in Kenya just like in many developing countries. Efficacy, availability, 
low cost and use in prevention of vertical HIV transmission are the key reasons for this choice (WHO, 2016). 
Unfortunately, NVP is associated with a higher incidence of rashes (van Leth et al., 2004), hepatotoxicity (Aizire 
et al., 2012) and a low genetic barrier to resistance limiting the use of this drug (Clutter et al., 2016). In some 
countries especially, the developed countries the drug is no longer dispensed. Several factors are pointed out 
affecting NVP plasma concentration. Pharmacogenetic factors such as the occurrence of single-nucleotide 
polymorphisms (SNPs) in the P450 2B6 (CYP2B6) and minorly by CYP3A have been extensively documented 
affecting NVP plasma concentration (Xu et al., 2012). The association between CYP2B6 SNPs and NVP plasma 
concentration has also been widely published in Kenya (Oluka et al., 2015); including among the population in 
the current study (Mungiria et al., 2020). Other factors affecting NVP plasma levels identified in other settings 
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but yet to gain much attention especially among the Kenyan population includes holistic socio-demographic, 
nutritional and adherence related factors (Bennett et al., 2008; Wang et al., 2011).  
Data aimed at individualization of ART treatment in Kenya are key to successful ART treatment programs. 
This study rigorously evaluated the relationship between socio-demographic, nutritional and adherence related 
factors with NVP concentrations among HIV-1 patients receiving ART treatment in western and coastal Kenya. 
 
Methods 
Design and study population  
A cross-sectional study approved by the Kenya Medical Research Institutes’ (KEMRI) Scientific Review Unit 
(SERU) (KEMRI/SERU/CVR/002/3214) and NACOSTI (NACOSTI/P/19/11747/28173) was conducted 
between August, 2018 and January 2020. Patients recruited in this study were part of an ongoing study designed 
to establish a cost-effective laboratory method to monitor antiretroviral adherence in HIV-1 infected individuals 
on treatment in Kenya. The patients recruited in this study were those: (i) HIV-1 infected adults (aged above 18 
years), attending the two HIV treatment programs, (ii) willing to voluntarily give written informed consent, (iii) 
able to read either English or Kiswahili, (iii) be on ARV treatment for 12 months, (iv) be on nevirapine based 
first line ARV treatment regimen and (v) HIV patients with viral load results at month 12 of treatment. All 
patients filled in a written informed consent for study participation 
 
Data collection 
Detailed description of the population of the study has been described previously (Mungiria et al., 2020). The 
study recruited 272 patients from Kisumu (western region of Kenya) and 105 patients from Malindi (coastal 
region of Kenya). An exhaustive structured interview (including demographic data, clinical history, adherence, 
HIV stigma and medical history) was used to collect patient-related information. From each patient, about 5 ml 
of intravenous blood was collected into ethylenediaminetetraacetic acid (EDTA)-containing Vacutainers® (BD, 
US) for determination of NVP plasma concentration measurement using a tandem quadrupole mass spectrometer 
designed for ultra-high performance: Xevo TQ-S (Waters Corporation, U.S.A) as described by Reddy et al. 
(2016). The NVP plasma concentration was categorized as <3100 ng/mL (below therapeutic range), 3100–4300 
ng/mL (therapeutic range) and >4300 ng/mL (above therapeutic range) as previously defined (Gopalan et al., 
2017; Mungiria et al., 2020). 
 
Data analysis 
Frequencies and percentages were used to present the sociodemographic data. The effect of socio-demographic, 
nutritional and adherence on NVP plasma concentrations was determined using Kruskal-Wallis test and Dunn’s 
test at α = 0.05. Univariate and multivariate linear regression analyses were performed to determine the 
relationship between NVP plasma concentration and Socio-demographic, nutritional and adherence and other 
clinical characteristics at 5% significance level. All statistical analyses were performed using STATA v 13 
(StataCorp LP, Texas, USA).  
 
Results  
Baseline characteristics  
The results from the all the 377 patients were assessed, of whom 272 (72.2%) were from Kisumu county 
(western region of Kenya), 223 (59.2%) were female and 114 (30.2%) had a HIV viral load of >1000 copies/mL. 
The median age of the patients was 41 years (IQR = 34–49 years), with a median duration of living with HIV 
infection of five years (IQR = 1–11years) and a median duration since ART initiation of three years (IQR = 1–8 
years). The median BMI of the patients was 25 kg/m2 (IQR = 22.2 - 28.7 kg/m2). There were 988(26%) of the 
patients whose staple food stuff was protein and carbohydrates with 264(70%) reporting lacking staple foods 
during the study. At the time of the study, there were 169 (44.8%) patients taking lamivudine, nevirapine, 
tenofovir regimen, with 205 (54.4%) reporting missing taking current ART at least once (Table 1). 
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Table 1. Summary of patient demographics and clinical characteristics of patients  
Variables
Region - Kisumu, n (%) 272 72.2
Female, n (%) 223 59.2
Age (years), Median (IQR) 41 (34 - 49)
HIV-RNA <1000copies/mL copies/mL,  n (%) 263 69.8
Time to HIVclinic (Minutes) Median (IQR) 60 (40 - 90)
Duration with HIV (Years), Median (IQR) 5 (1 - 11)
Age of sexual debut (Years), Median (IQR) 18 (16 - 20)
Duration post ART initiation (Years), Median (IQR) 3 (1 - 8) 
BMI (kg/m2), median (IQR) 25 22.2 - 28.7
Staple food stuff (Proteins/Carbohydrates) n (%) 98 26
Missed staple food n (%) 264 70
Porridge consumption (≥ 2 times) n (%) 147 39
Initial ARV Type
Lamivudine, Nevirapine, Stavudine 131 34.7
Lamivudine, Nevirapine, Zidovudine 134 35.6
Lamivudine, Nevirapine, Tenofovir 112 29.7
Changed ARV, yes n (%) 113 30
Current ARV Type
Lamivudine, Nevirapine, Stavudine 83 22
Lamivudine, Nevirapine, Zidovudine 125 23.2
Lamivudine, Nevirapine, Tenofovir 169 44.8
Missed taking current ART n (%) 205 54.4
76 - 100 % uptake of current ART n (%) 345 91.5
Missed taking ART n (%) 27 7.2
Total (N = 377)
 
NVP plasma concentration  
The steady-state NVP plasma concentrations ranged from 4 to 44,207 ng/mL (median 5179, IQR 2557–7453 
ng/mL) varying widely among patients. There were 96 (n = 377, 25.5%) patients with NVP concentration <3100 
ng/mL and 26 (n = 377, 6.9%) with NVP concentration of 3100-4300 ng/mL, with the majority, 255 (n = 377, 
67.6%), of the patients having an NVP concentration >4300 ng/mL. The steady-state plasma nevirapine 
concentrations was tested for normality by the Shapiro- Wilk test, and subsequently log10-transformed due to 
lack of normality (Shapiro- Wilk test = 0.86194; v = 36.048; p = 0.000001). 
Linear regression model  
Socio-demographic characteristics 
In the final linear regression model, sociodemographic factors significantly associated with a higher NVP 
concentration included region of origin (adjusted β 976, 95% CI, 183.2 to 1768.82; p = 0.016) and gender 
(adjusted β 670, 95% CI, 293.6 to 1634.2; p = 0.047). Education level on the other hand was associated with a 
lower NVP were education level (adjusted β -39.0779, 95% CI, -39.07 to 1085.7; p = 0.068, (Table 2) 
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Table 2. Univariate and multivariable regression analyses of Socio-demographic factors associated with 
NVP plasma concentrations.  
Variable
Unadjusted β P-value Adjusted β P-value
Age 282.5 -86.9 651.9 0.133 393 -168.7 954.0 0.17
Gender 612 -329.1 1553.1 0.089 670 293.6 1634.2 0.047
Religion -769 -3173.9 1635.9 0.53 -648 -2731.8 1435.1 0.541
Education 565 -18.4 1148.4 0.058 502 60.6 943.4 0.026
Ever been married 60 -1187.6 1307.6 0.925 -335 -2299.5 1628.9 0.737
Currently Married 250 -935.6 1435.6 0.679 251 -698.1 1200.7 0.603
Region 670 -218.2 1558.2 0.139 976 183.2 1768.8 0.016
Ethnicity -412.5 -862.9 37.9 0.073 -333 -845 179 0.202
Alcohol use -18.5 -1145.2 1108.2 0.974 25.6 -953.2 1004.4 0.959
Smoking -97 -3126.2 2932.2 0.95 127.1 -2167.4 2421.6 0.913
Bivariate Multivariate
 (95% CI)  (95% CI)
 
 
Nutritional factors  
None of the nutritional related factors were found associated with NVP plasma concentration (Table 3). 
Table 3. Univariate and multivariable regression analyses of nutritional factors associated with NVP 
plasma concentrations.  
Variable
Unadjusted β P-value Adjusted β P-value
Body Mass Index (Kg/M2) -51.5 -358 255 0.741 -92.2 -589.1 404.7 0.715
Types of stable food stuff -132 -428.3 164.3 0.382 -120.6 -319.6 78.4 0.234
Access  to staple food 1958 -2139.8 6055.8 0.348 1826.6 -1683.2 5336.4 0.307
Missed staple food 435 -141.1 1011.1 0.138 351 -507.1 1209.1 0.422
No of times missed staple food -125 -1512.8 1262.8 0.86 -441.1 -1646.9 764.6 0.472
Meal preparation 290 -659.6 1239.6 0.549 196.7 -436.4 829.7 0.542
Porridge consumption 49.5 -491.2 590.2 0.857 -40.4 -677.5 596.6 0.901
 (95% CI)  (95% CI)
Bivariate Multivariate
  
ART treatment and adherence related factors  
Table 4 describes linear regression analysis estimating the relationships between NVP and plasma levels and 
ART history and adherence factors. In multivariate analysis, initial ART regimen type (adjusted β = -548.1, 95% 
C = -904.2 to -192; p = 0.003) and ARV uptake in the past 30 days (adjusted β = -1109, 95% C = -2135 to -83; 
p = 0.034) remained independently associated with NVP plasma levels. 
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Table 4. Univariate and multivariable regression analyses of ART treatment and adherence related 
factors associated with NVP plasma concentrations.  
Variable
Unadjusted β P-value Adjusted β P-value
Time taken to ARV clinic (Minutes) 3.1 -6.4 12.5 0.528 191.4 -1175.4 1558.2 0.783
Fare to ARV clinic (Ksh) 121 -849.2 1091.2 0.806 -1084.5 -3149.4 980.5 0.302
Hospital Admission -1279 -2622.7 64.7 0.062 1100.6 -3033.7 1294.9 0.43
No of times missed HIV medical visits 602.5 -74.3 1279.3 0.081 393.3 -415.5 1131.3 0.363
Missed ART schedulled visit 111 -934.6 1156.6 0.835 605.4 -854.1 1526.8 0.579
Duration post ART initiation (Years) -39 -615.6 537.6 0.894 435.7 -1429.6 2300.9 0.646
Initial ARV Type -506.8 -778.9 -234.6 0.0001 -548.1 -904.2 -192 0.003
Changed ARV -1238 -1895.9 -580.1 0.0001 -159.6 -1233.7 914.6 0.77
Current ARV Type 87 -894.1 1068.1 0.862 523.5 -651.3 1698.2 0.381
Missed taking current ART -986 -1661.1 -310.9 0.004 -192.9 -1173.5 787.7 0.304
Percent uptake of current ART (%) -43.8 -81.5 -6.1 0.023 68.5 -2295.2 2432.3 0.955
Missed taking past ART -906 -1861.1 49.1 0.063 -602.4 -3362.2 2157.3 0.668
Missed ARV uptake 4 to 14 days -441 -1262.4 380.4 0.292 67 -1097.0 1231.0 0.91
Missed ARV uptake ≥ 14 days -447 -1476.3 582.3 0.394 -613.5 -1954.3 727.3 0.369
ARV dose missed yesterday -2959 -4795.1 -1122.9 0.002 -2097.5 -4825.7 630.7 0.131
ARV dose missed in the past 2 days -1457.5 -4089.8 1174.8 0.277 1183.5 -936.5 3303.5 0.273
ARV dose missed in the past 3 days -2517.5 -4070.9 -964.1 0.002 -2059.5 -4696.9 577.9 0.126
ARV uptake in past 30 days -822 -1625.5 -18.5 0.045 -1109 -2135 -83 0.034
ARV dose missed in the past 30 days -179 -1048.4 690.4 0.686 -176 -939.9 587.9 0.651
 (95% CI)  (95% CI)
Bivariate Multivariate
Discussion  
Efforts contributing to the personalization of ART treatment aimed at prolonging life of persons living with HIV 
marks huge component of HIV treatment programs in many countries. The recommendation by WHO requiring 
immediate initiate ART treatment to people testing HIV positive regardless of their CD4 or viral load (UNAIDS, 
2016), must also take cognizant of the fact that optimal ART outcomes inevitably requires an understanding of 
the individual variation in response to ART, both efficacy and toxicity. ART treatment outcomes are influenced 
in part by host pharmacoecologic factors (Phillips and Mallal, 2009). The pharmacoecologic factors include 
factors relating to lifestyle and adherence of the patient, drug interactions or pregnancy (Pavlos and Phillips, 
2012). Patients demographic factors such as age, gender (Wyen et al., 2008; Swaminathan et al., 2011), 
nutritional status such as body weight, growth rate (Schipani et al., 2011) are also shown to influence the 
treatment outcomes attributed (Gopalan et al., 2017). This study evaluated the influence of socio- demographic 
factors (such as age, sex, education level), nutritional status and ARV treatment and adherence on the steady-
state plasma concentrations of nevirapine among HIV patients receiving treatment in two regions of Kenya 
known for high prevalence of HIV as well as uptake of ART treatment in Kenya. 
We reported wide interindividual variability in NVP plasma levels ranging from 4ng/mL to 44,207 ng/mL 
(median 5179 ng/mL, IQR 2557–7453 ng/mL). This range is far broader than those reported in other studies 
(Oluka et al., 2015; Giacomelli et al., 2018; Mazanderani et al., 2019). There were 255(67.6%) patients with 
NVP plasma of 3000 to 8000 ng/mL (la Porte et al., 2006) considered within therapeutic range. Further, there 
were 25.5% patients who had NVP plasma levels of <3100 ng/ml, correlated with poor viral suppression (la 
Porte et al., 2006). Previous studies in Kenya and in other countries such as Italy have reported fewer cases of 
persons with NVP plasma level of levels of <3100 ng/ml (Oluka et al., 2015; Giacomell et al., 2018). 
Region of origin contributed significantly to NVP plasma concentration with the patients from coastal 
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Kenya region having higher median NVP plasma concentration than those from Western Kenya region. A 
similar observation was made among the Bantu-related communities from Serowe/Palapye and Chobe districts, 
and the San-related communities of the Ghanzi area in Botswana (Tawe et al., 2018). Kenya's ethnic groups can 
be divided into three broad linguistic groups: Bantu (mostly in the Central Kenya), Nilotic (western Kenya) and 
Cushite (Coastal and Northern Kenya). Although these ethnic groups reside in close proximity to each other, 
there is wide environmental and cultural diversity between these populations (Kenya National Bureau of 
Statistics, 2019). Consequently, there exist wide host genetic and environmental diversity which may result in 
different efficacy and adverse event profiles or treatment outcome between different African populations treated 
with same ART regimen (Ngaimisi et al., 2013). The human cytochrome P450 2B6 enzyme (CYP2B6) plays a 
pivotal role in the metabolism of different drugs used for HIV life-long therapy (non-nucleoside reverse-
transcriptase inhibitors such as efavirenz and nevirapine). CYP2B6 is a highly polymorphic enzyme that affects 
the therapeutic response including drug interactions in individuals (Hedrich et al., 2016). Importantly, African 
populations show a high degree of variation in the CYP2B6 gene (Čolić et al., 2015). 
Males in this study tended to have elevated median NVP plasma concentration than female contrary to 
several independent studies (Gonzalez et al., 2005; Shiau et al., 2014; Giacomell et al., 2018). Generally, the 
difference in ARV plasma levels by gender has been attributed to the difference in body size and drug clearance 
between males and females. Although not significant, the older patients had higher median NVP plasma level 
than younger ones. This is consistent with other studies which have indicated that nevirapine metabolism in 
younger population is generally more rapid than older population, and that younger population including 
children require higher doses of nevirapine to achieve therapeutic concentration (Swaminathan et al., 2011; 
Gopalan et al., 2017). 
The observed association between education level and NVP plasma levels suggests that literacy, formal 
education and possibly Koranic education may impact favorably on adherence to ART with better treatment 
outcome (Hegazi et al., 2010). 
We did not observe an association with NVP plasma concentration and nutritional related factors such as 
body mass index, regular uptake of porridge, availability of balanced diet and access to staple food. However, 
patients with BMI of >30kg/m2 (obese), accessed balanced diet and regularly consumed porridge tended to have 
higher NVP plasma concentration. Studies have associated body composition, nutritional status, food security 
with NVP plasma concentration (Vreeman et al., 2014; Bartelink et al., (2015). The lack of proper nutrition 
and/or a diet low in fat are shown to affect ARV absorption, or ARV cellular transport (Lamorde et al., 2012).  
We observed the importance of initial ART regimen type and ARV uptake in the past 30 days influencing 
NVP plasma concentration. Access to ART is only one aspect of an effective HIV management programme 
(Moosa et al., 2019). Optimal adherence to ART is essential and early studies reported that ≥95% adherence to 
ART was required to achieve and maintain viral suppression (Paterson et al., 2000). Although recent studies 
have shown that virologic suppression may still be achieved with < 95% adherence levels, this is dependent on 
the ART regimen, duration of treatment and previous ART exposure (Talam et al., 2008; Ammassari et al., 
2016). Furthermore, repeated adherence levels of < 100% and treatment interruptions are associated with an 
increased risk of both NRTI and NNRTI resistance which form the backbone of current first line ART regimens 
in Kenya and many other developing nations (Haberer et al., 2015; Kimulwo et al., 2017). The important ART 
regimen type and adherence to treatment cannot be overemphasized in achieving HIV treatment success. 
Some of the limitation to this study included: First, the use of an NVP-based ART regimen in Kenya and 
other developed countries has been reduced if not eliminated in the recent past, limiting the generalization of 
these results. Secondly, this study did not delve deeper into ethnic profiling of study participants and the actual 
influence of ethnicity to treatment outcome cannot be ruled out. Lastly the cross-sectional nature of this study 
only permitted the description of the relationship between NVP plasma concentrations the stated 
pharmacoecologic factors and not a causal conclusion. Such outcomes can be confirmed in a longitudinal study.  
Recognizing these limitations, the following can be concluded, NVP plasma concentration is highly 
heterogenous with a significant proportion of these patients reporting levels of <3100 ng/ml, correlated with poor 
viral suppression. The host pharmacoecologic factors, such as gender, age, weight, education level, region of 
origin (ethnicity), ART regimen type and adherence, are key in influencing NVP plasma concentration. Taking 
these factors into consideration, HIV treatment may be personalized to achieve optimal treatment success  
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